Peptide-Based Nanoparticle for Tumor Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Conventional cancer therapies face limitations like toxicity and drug resistance.
• Nanotechnology, especially peptide-based nanoparticles (NPs), presents a viable alternative.
• Peptides offer biocompatibility, specificity, and biodegradability for targeted drug delivery.

Purpose of the Study:

• To review recent advancements in peptide-based nanoparticle systems for cancer therapy.
• To discuss mechanisms of peptide self-assembly and types of peptide NPs.
• To highlight strategies for enhancing therapeutic efficacy and overcoming clinical translation challenges.

Main Methods:

• Comprehensive review of recent scientific literature on peptide nanoparticles.
• Analysis of peptide self-assembly mechanisms (amphiphilicity, non-covalent interactions, metal coordination).
• Categorization of peptide NPs into non-bioactive and bioactive systems.

Main Results:

• Peptide NPs can be designed as simple drug carriers or incorporate bioactive peptides for enhanced targeting and efficacy.
• Innovative designs include active targeting, stimuli-responsive release, and immunomodulatory strategies.
• Preclinical studies show promise, but clinical translation faces hurdles in stability, delivery, and manufacturing.

Conclusions:

• Peptide nanoparticles hold significant potential for advanced cancer treatment.
• Overcoming challenges in stability, delivery, and manufacturing is crucial for clinical success.
• Future directions include personalized nanomedicine, combination therapies, and advanced peptide engineering.